Fintech PR
March – Introduce More Carrots in Your Diet
Although carrots are available throughout the year, carrots grown at local, seasonal, summer and autumn season are more preferable because they are fresher and more delicious. Carrots are part of the Umbelliferae family, called after-umbrella, like clusters of flowers radiates from a single point. Per se, carrots are closely related as a family of, fennel, parsley, anise, cumin, caraway and dill.
We are fortunate to have the results of a new 10-year study in the Netherlands with carrots and the risk of cardiovascular disease (CVD) – and these results are really fascinating. The fruit and vegetable input in the study was classified by color and focused on four color categories: green, orange / yellow, red / violet, white. Of these four categories, orange / yellow (and, in particular, deep orange and yellow foods) have been the most beneficial and protective against cardiovascular diseases. Participants who ate at least 25 grams of carrots (25 grams, less than one quarter of a cup) had a significantly lower risk of CVD. Groups of participants who ate 50 or 75 grams more had an even lower risk of CVD!
Much of the research has focused on carotenoids in carrots and their important antioxidant benefits. After all, carrots (along with pumpkin and spinach) have a high ranking on the list of legumes considered antioxidants, commonly consumed in the US. But recent studies have come to the conclusion and brought the carrot as a part of nutrients called phytonutrients. In carrots, the most important components are polyacetylenes, falcarinol and falcarindiol. Several recent studies have identified these polyacetylenes in carrot as phytonutrients that can help inhibit the growth of colon cancer cells. These new findings are exciting because they suggest a key interaction between carotenoids and polyacetylenes carrots. Apparently, rich carotenoid content in carrots helps prevent oxidative damage not only inside our body but can also help prevent oxidative damage. In other words, these two stunning groups of carrot phytonutrients can work together in a synergistic way to maximize their benefits in our health!
Carrots have been found to have a better taste, while cooked steam! In a recent study on examining different methods in cooking vegetables, study participants were asked to evaluate the flavor and taste, the overall acceptability of the results. Compared with boiling points, study participants significantly favored the general taste and acceptability of steamed carrots, as compared to boiled ones.
Raw Carrots, slices
1.00 cup
(122.00 grams) Calories: 50
GI: low
NutrientDRI / DV
– vitamin A113%, biotin20%, vitamin K18%, fibre14%, molybdenum14%, potassium11%, vitamin C10%, vitamin B610%, mangan9%, vitamin B38%, vitamin B17%, pantothenic acid7%, copper6, phosphorus6%, folate6%, vitamin B25%, vitamin E5%
Carrots are probably best known for providing rich nutrients and antioxidants, which was actually called: beta-carotene. However, these delicious root vegetables are the source of not only beta-carotene, but also contain a wide variety of antioxidants and other nutrients. They are beneficial in cardiovascular problems but are also anti-cancer nutrients.
Antioxidant benefits
All carrot varieties contain significant amounts of antioxidant nutrients. Included here are traditional antioxidants, such as vitamin C, as well as phytonutrient antioxidants such as beta-carotene. The list includes:
carotenoids
alpha-carotene
beta-carotene
lutein
Hydroxycinnamic acids
caffeic acid
Coumaric acid
Ferulic acid
Anthocyanidins
cyanidins
malvidin
Different varieties of carrots contain different amounts of these antioxidant phytonutrients. Red and purple carrots, for example, are best known for their rich anthocyanin content. The oranges are particularly remarkable in terms of beta-carotene content, which accounts for 65% of their total carotenoid content. In yellow carrots, 50% of all carotenoids come from lutein.
Cardiovascular benefits
Given their richness in antioxidants, it is not surprising to find many studies about it. Our cardiovascular system needs constant protection. Thus they (carrots) are considered cardioprotective.
The anti-cancer benefits
The anti-cancer benefits of carrot have been proven in the prevention and treatment of colon cancer. Part of this research involved the actual intake of carrot juice by the participants, as well as other research that involved studies on different types of cancer cells.
“Baby” carrots are rich in nutrients and low in calories and are ideal for raw or steam snacks or in a mixture of vegetables.
What do they contain?
Vitamin A
Vitamin A is the nutrient found in carrots of all types and varieties. Each minced “cup” contains 21384 IUs – international units. The daily dose, for example recommended for women, is 2,300 IU, or 700 micrograms. Vitamin A helps ensure good vision, healthy skin and proper functioning of the immune system. For the reproduction of a cell, we need vitamin A, but it also participates in bone formation. Vitamin A in carrot comes in the form of beta-carotene, which the body turns into vitamin A during digestion. Although carrot consumption is beneficial, taking large amounts of vitamin A through supplements can cause toxicity.
Fiber
A cup of baby-chopped carrots or large carrots contains 3.6 grams of dietary fiber, which is up 10 percent of the amount we need in a day. Fiber supports digestion, regland and helping constipated people. Fiber-rich diets are also linked to lowering cholesterol levels, reducing the risk of diabetes and preventing colon cancer. Foods rich in fiber are also useful for weight control, adding the amount of free calories to food.
Vitamin K
Vitamin K is an essential vitamin that plays a role in blood clotting and the production of certain bone proteins. A cup of baby-carrots or chopped carrots contains about 17 micrograms of vitamin K; adult women need 90 micrograms per day. Other excellent sources of vitamin K are everything that is green and dark green, leaves such as cabbage, spinach, and broccoli and soybean oil. If you take any anticoagulant, such as warfarin, it can not be taken safely with large amounts of vitamin K.
C vitamin
At 7.6 milligrams of vitamin C per cup of minced carrots, carrots provide about 10 per cent of the 75 milligram daily needed for women. Our body uses vitamin C for a lot of functions, including immune support, cell repair and wound healing. Vitamin C also helps you absorb iron from food, which is especially important for menstruation in women. However, there is no truth in that myth, which tells us that consuming large amounts of vitamin C helps prevent colds. Although vitamin C supplements can regularly reduce the duration of colds. They play an important role in cancers and tumors, being antitumor, and yes they play an important role in fighting various viruses and bacteria, etc.
Our carrot vegan cream soup contains:
A bigger handful of baby carrots, a tiny root of parsley, a half of white onion (or leeks), 1 tablespoon organic coconut butter, a little Himalayan salt, spring water – mix together in the blender and get serve with dry mint (vegetables can boil light in steam, or you can make the soup in their raw state)
HANOI, Vietnam, Dec. 4, 2024 /PRNewswire/ — KuCoin, a leading global exchange, has proudly hosted an enlightening substage session at the prestigious VTIS event on December 3rd, drawing a crowd of over 300 participants to Stage C with 4 insightful panels and 2 inspiring speeches. The session, themed “Next-Gen Consumer Apps and the Digital Economy,” offered a profound exploration into the transformative potential of digital assets.
During this pivotal event, visionaries, industry leaders, and enthusiasts gathered to delve into how digital assets revolutionize consumer experiences and the broader economic landscape. The session presented an array of discussions ranging from payments to blockchain’s role in consumer applications, focusing on the immense opportunities within the ASEAN market.
A panel on the “Next Generation of Payment” kicked things off, featuring innovators like Hieu Do (Head of Partnership of Holdstation), Cody Li (Founder of Terminus.network), and Cem Arcan (Head of Ecosystem of Next Generation). This was followed by a panel discussion on “Building Digital Markets with RWA,” where Mary Tran (CEO of Orochi Network), Wynn Le (Manager Director of SSI Digital), and CK Ong (COO of SBI Digital Market) shared their expertise.
Raymond Chu, Director of Thailand International Digital Business & Finance Center (TIDC), then delivered a keynote on “A Gateway to Southeast Asian Digital Growth,” highlighting the region’s unique market dynamics. The afternoon sessions also included a deep dive into “Future Innovation and Security in Blockchain,” with contributions from Celine Chong (Sales Engineer of Figment), Vi Vi (Co-Founder of ZKP Labs), and Will Huang (Ecosystem Lead of TONX). Yuki Zhou (HK Hub Lead of TON Society), Jenny Nguyen (COO of Kyros Ventures), Son Ho (MD and Head of Investment of k300 ventures) and Vanny Ha (Head of Vietnam of Kaia LTD Foundation) then took the stage to discuss Web3 Consumer App in ASEAN Market.
The event concluded with a keynote from Trần Kim Duy Lân, Lecturer of HUTECH University, focusing on the future impact of technology on blockchain and AI. The “Blockchain & Fintech Fiesta” networking hour wrapped up the event, fostering connections and discussions among innovators, industry shapers, youngsters and enthusiasts.
“We are glad to have hosted the event at the prestigious Vietnam National Convention Center, together with leading financial and technology companies like SSI Securities Corporation (SSI) and FPT,” said Alicia Kao, Managing Director of KuCoin. “KuCoin will continue to support the AI and blockchain technology innovation in Vietnam and provide platform and resource to the local community in education, incubation and mentorship.”
KuCoin has also collaborated with volunteers from prestigious Vietnamese universities, including Diplomatic Academy of Vietnam, Foreign Trade University, Academy of Journalism and Communicationand etc, offering enriching experiences and learning opportunities for the younger generation interested in blockchain, AI, and fintech industries. This partnership highlights KuCoin’s commitment to educational development. It stands as a cornerstone of KuCoin’s global corporate social responsibility initiatives, aiming to foster a knowledgeable and skilled future workforce in the rapidly evolving tech landscape.
About KuCoin
Founded in 2017, KuCoin is one of the pioneering and most globally recognized technology platforms supporting digital economies, built on a robust foundation of cutting-edge blockchain infrastructure, liquidity solutions, and an exceptional user experience. With a connected user base exceeding 37 million worldwide, KuCoin offers comprehensive digital asset solutions across wallets, trading, wealth management, payments, research, ventures, and AI-powered bots. KuCoin has garnered accolades such as “Best Crypto Apps & Exchanges” by Forbes and has been recognized among the “Top 50 Global Unicorns” by Hurun in 2024. These recognitions reflect its commitment to user-centric principles and core values, which include integrity, accountability, collaboration, and a relentless pursuit of excellence.
Photo – https://mma.prnewswire.com/media/2573030/image_5002362_6536045.jpg
Photo – https://mma.prnewswire.com/media/2573129/12_4_3.jpg
Photo – https://mma.prnewswire.com/media/2573211/3.jpg
Logo – https://mma.prnewswire.com/media/2356857/KuCoin_Horizontal_Green_LOGO_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/a-glimpse-into-the-future-with-kucoin-at-vtis-2024-302322191.html
— Round led by Versant Ventures with participation from founding investor Novo Holdings and new investors SR One, Dawn Biopharma and Pictet–
–Entering Phase I testing for next-generation weight loss therapy by antagonizing GIPR–
COPENHAGEN, Denmark, Dec. 4, 2024 /PRNewswire/ — Antag Therapeutics, a next-generation biopharmaceutical company pioneering novel treatments for obesity, today announced the closing of an €80 million Series A financing. The round was led by Versant Ventures, with participation from Novo Holdings, SR One, Dawn Biopharma (a platform controlled by KKR), Pictet, Longview Ventures (an affiliate of Broadview Ventures), and Export and Investment Fund of Denmark (EIFO). The funds will support the clinical development of AT-7687, a novel, once-weekly subcutaneous antagonist of the Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR), and also fueling the expansion of Antag’s pipeline of monthly injectable therapies.
GLP-1-based therapies have revolutionized obesity management, but for some patients can cause tolerability issues, loss of muscle mass, and suboptimal weight-loss. This highlights the need for complementary pharmacological approaches.
The genetic basis for antagonizing GIPR is clear. Individuals with naturally occurring genetic GIPR variants that reduce its activity have lower BMI and body fat percentages, resulting in a leaner phenotype compared to those with normal GIPR function.
The development of Antag’s lead molecule is rooted in the groundbreaking identification of an endogenous GIPR antagonist by University of Copenhagen professors Jens Holst, renowned for his discovery of GLP-1, and Mette Rosenkilde. Both co-founded Antag and bring extensive expertise in incretin biology spanning decades. Professor Holst also chairs Antag’s scientific advisory board.
AT-7687 is a peptide designed to be co-administrated with current or future obesity therapies including GLP-1 medicines to deliver superior weight loss and metabolic benefits. This flexibility in dosing provides multiple advantages over competing GIPR blockers such as antibodies directly conjugated to GLP-1. These include the ability to optimally drug each target for maximal efficacy and tolerability. In addition, AT-7687 also can be used as a single agent in the maintenance setting.
In non-human primate studies, AT-7687 plus a GLP-1 produced best-in-industry weight loss. Furthermore, AT-7687 improved glycemic control and lipid profiles independent of weight changes. Importantly, these benefits were achieved without gastrointestinal side effects.
The U.S. Food and Drug Administration (FDA) recently accepted Antag’s Investigational New Drug (IND) application for AT-7687, setting the stage for clinical development to begin early next year. The trials will explore the effects of AT-7687 as both a monotherapy and in combination with a GLP-1 receptor agonist in obese patients. Antag’s pipeline also includes combinations beyond GLP-1 receptor agonists and a follow-on molecule that enables monthly administration.
“The backing of such a strong syndicate of global investors is a testament to our pioneering approach to developing novel therapies for patients with obesity,” said Alexander Hovard Sparre-Ulrich, Ph.D., CEO and co-founder of Antag. “Coupled with our recent IND clearance, this investment allows us to accelerate the development of AT-7687 towards important clinical milestones. We believe our first-in-class peptide’s weight loss profile and flexible dosing will be key drivers of differentiation.”
“Antag’s peptides will have important advantages given their ability to be used alone or optimally combined with other incretin-based agents, in both weekly or monthly formats,” said Alex Mayweg, Ph.D., Managing Director at Versant and an Antag board member. “GIP receptor antagonism is just beginning to reveal its incredible potential, both in diabetic and non-diabetic obesity, and we are pleased to be at the forefront of this developing field.”
“Novo Holdings was the first investor in Antag and we were excited by great science and a world-renowned founder team,” said Jeroen Bakker, Partner, Seed Investments, Novo Holdings. “We are proud to close this Series A round, which brings several blue-chip investors on board. This funding marks a pivotal step in advancing Antag’s pipeline, which we are confident could play a crucial role in further improving the lives of people with obesity.”
About Antag Therapeutics
Antag Therapeutics is a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies for obesity and cardiometabolic diseases through GIP receptor antagonism. As a pioneer in exploring the potential of GIP receptor antagonists, the company is dedicated to advancing science and improving patient outcomes by delivering groundbreaking solutions that address unmet medical needs. For more information, please visit https://antagtherapeutics.com.
About Versant Ventures
Versant Ventures is a leading healthcare venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm’s emphasis is on biotechnology companies that are discovering and developing novel therapeutics. With $5.5 billion under management and offices in the U.S., Canada and Europe, Versant has built a team with deep investment, operating and R&D expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, more than 100 Versant companies have achieved successful acquisitions or IPOs. For more information, please visit www.versantventures.com.
About Novo Holdings A/S
Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Asia, Planetary Health and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development. As of year-end 2023, Novo Holdings had total assets of EUR 149 billion. www.novoholdings.dk
About the Novo Nordisk Foundation
Established in Denmark in 1924, the Novo Nordisk Foundation is an enterprise foundation with philanthropic objectives. The vision of the Foundation is to improve people’s health and the sustainability of society and the planet. The Foundation’s mission is to progress research and innovation in the prevention and treatment of cardiometabolic and infectious diseases as well as to advance knowledge and solutions to support a green transformation of society.
View original content:https://www.prnewswire.co.uk/news-releases/antag-therapeutics-announces-80-million-series-a-financing-302321184.html
LONDON, Dec. 4, 2024 /PRNewswire/ — The Fortegra Group, Inc. (“Fortegra” or “the Company”), a global specialty insurer and subsidiary of Tiptree Inc. (NASDAQ: TIPT), today announced that it has received approval to establish Fortegra Insurance Company UK.
The Prudential Regulation Authority (PRA) has granted Fortegra approval to establish its subsidiary in the United Kingdom, effective November 29, 2024. This milestone enables Fortegra to significantly expand its specialty insurance underwriting services throughout the United Kingdom.
Recognised as a quality market for Managing General Agents (MGAs) and Managing General Underwriters (MGUs), Fortegra excels through its rigorous programme business underwriting, advanced AI and data science applications, and a steadfast commitment to consistent claims management. Fortegra’s underwriting approach ensures that the company effectively meets the evolving needs of agent partners and policyholders, cementing its market leadership.
“We’re pleased to announce the establishment of Fortegra Insurance Company UK,” said Richard Kahlbaugh, Fortegra’s chief executive officer. “Our objective is simple. We focus our efforts on establishing Fortegra as a quality market serving MGAs and agents seeking to underwrite niche programmes. The foundation of our past success, underwriting discipline, will serve Fortegra well as we enter the marketplace in the United Kingdom.”
The licensing of Fortegra UK provides an excellent opportunity to enhance the company’s presence in the UK and London markets, demonstrating its commitment to expanding in Europe. This strategic initiative builds on previous successes in Belgium and the EU.
Since entering the region in 2018, Fortegra has effectively expanded its reach through thoughtful geographic growth and establishing strong partnerships with reputable agents and MGAs. The company’s focus on delivering innovative and collaborative underwriting solutions positions it well for future growth and success.
About Fortegra
For more than 45 years, Fortegra, via its subsidiaries, has underwritten risk management solutions that help people and businesses succeed in the face of uncertainty. As a multinational specialty insurer whose insurance subsidiaries have an A.M. Best Financial Strength Rating of A- (Excellent) and an A.M. Best Financial Size Category of ‘X’, we offer a diverse set of admitted and excess and surplus lines insurance products and warranty solutions. For more information: www.fortegra.com.
Contact
[email protected]
View original content:https://www.prnewswire.co.uk/news-releases/fortegra-secures-licence-launches-new-uk-subsidiary-302321668.html
-
Fintech7 days agoFormer MD of SUI Foundation, Greg Siourounis, Joins xMoney Global as Co-Founder and CEO to build MiCA-Regulated Stablecoin Platform
-
Fintech5 days agoBanking and Capital Markets: Navigating a Complex Future
-
Fintech1 day agoFintech Pulse: Your Daily Industry Brief (PayPal, Apple Pay, Google Wallet, Introspective Market Research, Deel, Kingdom Advisors, Basta Pay)
-
Fintech PR4 days agoNoble Corporation plc announces changes to its share capital including share repurchases for the month of November 2024
-
Fintech PR6 days agoYunoJuno Recognised as Best International Contractor Provider, Revolutionising Global Freelance Management
-
Fintech PR7 days agoLONGi and IUCN jointly release the Initiative of Advancing Climate Action and Biodiversity Conservation with Photovoltaic
-
Fintech PR7 days agoMobile Wallet and Payment Market Skyrockets to $71.28 Billion by 2031 Dominated by Tech Giants – Paytm E-Commerce Pvt Ltd, Telefonaktiebolaget LM Ericsson and Early Warning Services, LLC | The Insight Partners
-
Fintech PR7 days agoADFW Unveils Full Agenda for 2024 Edition, One of the Most Impactful Financial Gatherings of the Year